A214610 Stock Overview
Provides on-site diagnostic systems based on Lab-on-a-Chip technology.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
MiCo BioMed Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩1,558.00 |
| 52 Week High | ₩5,608.44 |
| 52 Week Low | ₩1,132.00 |
| Beta | 0.58 |
| 11 Month Change | 18.03% |
| 3 Month Change | 5.63% |
| 1 Year Change | -60.97% |
| 33 Year Change | -89.13% |
| 5 Year Change | -77.17% |
| Change since IPO | -82.11% |
Recent News & Updates
Is MiCo BioMed (KOSDAQ:214610) Using Too Much Debt?
Aug 08
Is MiCo BioMed (KOSDAQ:214610) Using Debt In A Risky Way?
Apr 12Shareholder Returns
| A214610 | KR Medical Equipment | KR Market | |
|---|---|---|---|
| 7D | 17.4% | 0.9% | -7.3% |
| 1Y | -61.0% | 15.7% | -3.7% |
Return vs Industry: A214610 underperformed the KR Medical Equipment industry which returned 15.7% over the past year.
Return vs Market: A214610 underperformed the KR Market which returned -3.7% over the past year.
Price Volatility
| A214610 volatility | |
|---|---|
| A214610 Average Weekly Movement | 8.6% |
| Medical Equipment Industry Average Movement | 7.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in KR Market | 11.9% |
| 10% least volatile stocks in KR Market | 3.3% |
Stable Share Price: A214610 has not had significant price volatility in the past 3 months.
Volatility Over Time: A214610's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 88 | Young S Hong | www.micobiomed.com |
MiCo BioMed Co., Ltd. provides on-site diagnostic systems based on Lab-on-a-Chip technology. The company offers molecular diagnostics devices comprising Veri-Q PREP M16 (G2-16TU) System, a device which include, membrane to extract nucleic acid using tube; VERI-Q PCR 316, a device to get the result in a short time using plastic chip; VERI-Q PCR 204 (G2-4), a device to deliver the real-time PCR system; PCR and sample prep kits; and LabChip, sample tube, and pre-filtering column. It also provides biological chemistry products, including VERI-Q Multi, a cholesterol diagnostic product; VERI-Q Hb Mate and VERI-Q RED, a hemoglobin monitoring system; and VERI-Q PRO, a blood glucose monitoring system.
MiCo BioMed Co., Ltd. Fundamentals Summary
| A214610 fundamental statistics | |
|---|---|
| Market cap | ₩67.87b |
| Earnings (TTM) | -₩26.81b |
| Revenue (TTM) | ₩6.32b |
10.7x
P/S Ratio-2.5x
P/E RatioIs A214610 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A214610 income statement (TTM) | |
|---|---|
| Revenue | ₩6.32b |
| Cost of Revenue | ₩14.61b |
| Gross Profit | -₩8.30b |
| Other Expenses | ₩18.52b |
| Earnings | -₩26.81b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -615.56 |
| Gross Margin | -131.35% |
| Net Profit Margin | -424.45% |
| Debt/Equity Ratio | 18.2% |
How did A214610 perform over the long term?
See historical performance and comparison